



For patients with
metastatic breast,
colorectal, or
prostate cancer...

WHAT'S YOUR
NEXT
STEP?



Inform your
journey with...

Cell Search[®]
Circulating Tumor Cell Test

Guiding the way

THERE ARE SIGNS

ALONG YOUR JOURNEY...

Each year, thousands of people begin a personal journey when they are diagnosed with metastatic breast, colorectal, or prostate cancer. This journey can lead them down many paths, each requiring thoughtful choices along the way.

Metastatic cancer is a cancer that has spread from one tumor to other parts of the body. Many of the choices that are made are based on how the disease is progressing. To determine this, doctors look for signs, which traditionally are provided by imaging or tumor marker tests—or in the case of prostate cancer, prostate-specific antigen (PSA) tests—at certain points during therapy.



But now, there is another option. It's a different kind of test; one that can help you learn how you're doing sooner, monitor your prognosis at any point along your journey, and help your doctor in guiding your way.

It's called the...

CellSearch®
Circulating Tumor Cell Test

Guiding the way

For more information about the CellSearch® CTC Test, talk with your doctor or visit www.veridex.com.

STEPPING STONES THAT CAN OFFER DIRECTION SOONER...

Circulating tumor cells (CTCs) are cancer cells that have broken away from an existing tumor and have entered into the bloodstream.

The presence of these cells in your blood can provide valuable insight into the progression of your disease. Clinical studies have shown that the monitoring and detection of CTCs can actually predict whether a patient's prognosis is favorable or less favorable for those with certain metastatic cancers.*



Measuring the number of CTCs in your blood before and during treatment can help your doctor monitor your progress throughout your journey... and make more informed choices about your care.

That's why more and more doctors have been adding the *CellSearch® CTC Test* to their standard monitoring and testing methods.

Know where you stand at any time

The *CellSearch® CTC Test* is a simple blood test that captures, identifies, and counts CTCs. The test is so precise, it can detect as few as one CTC in a vial of blood.

Using a predetermined cutoff number—5 CTCs for metastatic breast and prostate cancer; 3 CTCs for metastatic colorectal cancer—the test can predict whether a patient's survival is favorable or less favorable. Clinical studies have shown that:

- If the number of CTCs is below the cutoff, indications are that the prognosis is favorable
- If the number of CTCs in a sample is above the cutoff, indications are that the disease may be progressing

By using the *CellSearch® CTC Test* before you start treatment, as early as after the first cycle of treatment, and at each step of the way, your doctor can monitor and determine your prognosis at any point along your journey.

*Breast, colorectal, or prostate



AND PROVIDE GREATER INSIGHT FOR THE PATH AHEAD . . .

Depending on the type of cancer a patient has, doctors use a combination of lab tests, physical exams, and imaging studies such as CT scans to monitor and determine progression of the disease.

For patients with metastatic breast or colorectal cancer, doctors typically use imaging to measure changes in tumor size to determine if a treatment is working. Imaging typically starts about 12 weeks after therapy has begun. Similarly, PSA testing, which is used for patients with metastatic prostate cancer, will also begin several weeks after the start of therapy.

When used in combination with these tests, the *CellSearch® CTC Test* not only allows your doctor to detect changes in your status sooner than by using other testing methods alone, it also provides a more complete picture of your prognosis at any point in time.

With this valuable information, your doctor can help you better plan your next steps...



The CellSearch® CTC Test at a glance

- The *CellSearch® CTC Test* is for patients with metastatic breast, colorectal, or prostate cancer
- It is a simple blood test that captures, identifies, and counts the number of CTCs in the patient's blood; this number is used to determine a patient's prognosis at any time
- Typically, a blood sample is taken for the CTC test right in the doctor's office before a new line of therapy begins (to establish a baseline), then at any time during the course of treatment to monitor the disease
- Because every patient is different, you should discuss with your doctor whether or not the test is right for you and how often it should be given
- You and your doctor can learn more about the test by going to www.veridex.com, or by calling **1-877-VERIDEX** and selecting option 6

CellSearch®
Circulating Tumor Cell Test

Guiding the way

EVERY JOURNEY

BEGINS WITH A FIRST STEP...



Ask your doctor about the simple blood test that provides:

Knowledge about patient prognosis

CTCs can predict how favorable your prognosis is at any time

Greater insight than standard tests alone

When used in combination with other monitoring tests, CTC testing provides a more complete picture of your prognosis

More informed decisions at any time

Monitoring CTCs can show a change in prognosis as early as after the first treatment cycle and at each step of the way

CellSearch®
Circulating Tumor Cell Test

Guiding the way

For more information, contact us at:

1-877-VERIDEX | www.veridex.com

VERIDEX
LLC
a Johnson & Johnson company

CellSearch® and related products are covered by one or more patents as described on www.veridex.com

CellSearch® is a registered trademark of Veridex, LLC © 2008 Veridex, LLC

4900179